Author Identifier

Daniel A Galvao

https://orcid.org/0000-0002-8209-2281

Robert U Newton

https://orcid.org/0000-0003-0302-6129

Document Type

Journal Article

Publication Title

Cancers

Volume

13

Issue

23

Publisher

MDPI

School

School of Medical and Health Sciences / Exercise Medicine Research Institute / Centre for Exercise and Sports Science Research

RAS ID

40502

Funders

Australian New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) through a Below the Belt research grant (Short 2017)

Commonwealth Research Training Program scholarship

Freemasons Centre for Men's Health

National Health and Medical Research Council

Victorian Cancer Agency

Grant Number

NHMRC Number : 1090517

Comments

Evans, H. E. L., Galvão, D. A., Forbes, C. C., Girard, D., Vandelanotte, C., Newton, R. U., . . . Short, C. E. (2021). Acceptability and preliminary efficacy of a web-and telephone-based personalised exercise intervention for individuals with metastatic prostate cancer: The exerciseguide pilot randomised controlled trial. Cancers, 13(23), Article 5925.

https://doi.org/10.3390/cancers13235925

Abstract

Preliminary research has shown the effectiveness of supervised exercise-based interventions in alleviating sequela resulting from metastatic prostate cancer. However, many individuals encounter barriers that limit the uptake of face-to-face exercise. Technology-enabled interventions offer a distance-based alternative. This pilot study aimed to explore the acceptability, safety and preliminary efficacy of a web-based exercise intervention (ExerciseGuide) in individuals with metastatic prostate cancer. Forty participants (70.2 ± 8.5 years) with metastatic prostate cancer were randomised into the 8-week intervention (N = 20) or a wait-list control (N = 20). The intervention arm had access to a computer-tailored website, personalised exercise prescription and remote supervision. ExerciseGuide was deemed acceptable with a score ≥ 20 on the client satisfaction questionnaire; however, the usability score was just below the pre-specified score of ≥ 68 on the software usability scale. There were no serious adverse events reported. Moderate-to-vigorous physical activity levels between baseline and follow-ups were significantly higher (10.0 min per day; 95% CI = (1.3–18.6); p = 0.01) in the intervention group compared to wait-list control. There were also greater improvements in step count (1332; 95% CI = (159–2505); p = 0.02) and identified motivation (0.4, 95% CI = (0.0, 0.7); p = 0.04). Our findings provide preliminary evidence that ExerciseGuide is acceptable, safe and efficacious among individuals with metastatic prostate cancer.

DOI

10.3390/cancers13235925

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

 
COinS